Core Insights - TC BioPharm has made significant progress in 2024, enhancing its position as a leading clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies for cancer and other indications [2][5] Operational Achievements - The ACHIEVE UK trial has advanced rapidly, with 8 patients dosed, including 2 who have received their final dose, all in Cohort A [2] - A new site has opened at Guy's and St. Thomas Hospital, a leading oncology clinic in the UK, with plans to open two more sites in Q1 2025 [2] - The compassionate use program for TCB008 has garnered interest from physicians in the UK and US, indicating its potential broad application in various cancer types [2] Financial Performance - In Q1 2024, the company reduced cash burn by 50%, aligning R&D efforts towards commercial applications [2] - Approximately $8 million in capital was added to the balance sheet in August through a non-brokered transaction with an investor group [2] Strategic Initiatives - TC BioPharm has signed two non-binding Letters of Intent (LOIs) for acquisitions in cell therapy modalities beyond TCB008 [2] - The company plans to initiate proof of concept for preclinical trials for Mpox treatment with a leading infectious disease expert in the UK [2] - A strategic partnership has been formed with a leading university for an AI initiative in donor screening for allogeneic cell therapies, a potentially multi-billion dollar market [2] Future Objectives - The company aims to continue executing its strategic initiatives and operational plans for 2025, including advancing Cohort B to a data readout and amending the Phase 1b FDA trial timeline [3] - TC BioPharm expects to compile clinical data for Cohort A in H1 2025 [3]
TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements